{"slideshow_credits": null, "snippet": "The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher.", "abstract": "Pfizer, in wake of failed $152 billion merger with Allergan, may break itself apart by end of 2016; some analysts say two smaller companies would be worth more than one big one; Pfizer's options are limited by new rules intended to restrict inversions.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}, {"firstname": "Chad", "role": "reported", "lastname": "BRAY", "rank": 2, "organization": ""}], "original": "By KATIE THOMAS and CHAD BRAY"}, "web_url": "http://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html", "lead_paragraph": "The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher.", "headline": {"main": "Pfizer Faces Limited Options After Its Dead Deal With Allergan", "print_headline": "Pfizer Weighs Split as Allergan Deal Collapses"}, "_id": "5704f14c38f0d848959befb0", "word_count": "929", "multimedia": [{"height": 126, "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 407, "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "407"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-04-07T04:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Pfizer Inc", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "ALLERGAN INC", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Corporate Taxes", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Allergan Inc", "is_major": "Y", "rank": "7"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}